Default company panoramic image

ViThera Pharmaceuticals, Inc

ViThera uses live biotherapeutics to treat diseases of the GI tract. Our lead product is for Crohn's Disease and Ulcerative Colitis.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Cambridge, MA, USA
  • Currency USD
  • Employees 3
  • Website

Company Summary

ViThera's lead program (VT301) revolutionizes treatment for patients with Inflammatory Bowel Disease, a significant unmet need. Existing drugs target the immune system but VT301 heals the epithelial lining of the gut without affecting the immune system. ViThera's approach is validated by an early partnership with J & J. ViThera follows an aggressive path to clinical proof of concept (2015) and pursues early exit opportunities.


  • Default avatar
    Johannes Fruehauf MD PhD
    President and CEO

    Successful serial entrepreneur, Founder Cambridge Biolabs, Cofounder Cequent, developed CEQ508 bench to bedside,
    13 therapeutic patents. Advisor to Avecia, Aura Biosciences, Marina Biotechnology, Biota, BMT, PCL, others

  • Default avatar
    Lisa Velardo

    Watermill Ventures, Vality, Boston Biomedical , Boston Heart Lab, Cequent Pharmaceuticals, Aspen Consulting, GnuBIO

  • Default avatar
    Peter D. Parker

    20 yrs life sciences investor, BioInnovation
    Ampersand, Cequent, Novex, Tomah, VITEX, Magellan Biosciences, Dynex, Pentose, Alexis, CoPharma, Panacos, TekCel, Cyclis

  • Default avatar
    R. Balfour Sartor, MD
    Head of SAB

    Key opinion leader IBD. Chair, Center for IBD Research and Treatment, UNC, Chief Medical Advisor to CCFA
    Specialist on bacteria-gut relationship

  • Default avatar
    Pamela Fekete MD, JD, MS

    IP attorney, 14yrs experience as research scientist, FDA consultant in pharmaceutical and biotechnology industries
    Neurogen, BAYER, FLH, Rembrandt IP, Cequent, EWP, BioInnovation, GnuBIO

  • Default avatar
    Philippe Langella

    Professor, Head, Probiotic and Commensal Laboratory, INRA, France. >25yrs research on Lactic acid bacteria.
    Consultant to Danone, Merck, Lallemand, Cequent
    Inventor of VT201 technology

  • Default avatar
    Grazyna Szymanska-Schellenberg
    VP Corporate Development

    Bio-Pharma entrepreneur, angel investor and technical consultant with over 20 years experience. Harvard Medical School, Curis, TolerRx, TEI Biosciences


  • Default avatar
    Peter B. Finn (Rubin & Rudman LLP)
    Default avatar
    Lisa Velardo, CPA - Chief Financial Officer

Previous Investors

  • Default avatar
    Johannes Fruehauf
    Default avatar
    J & J (equity convertible grant)